Your browser doesn't support javascript.
loading
Local anaesthetic adjuncts for peripheral nerve blockade.
Desai, Neel; Albrecht, Eric.
Afiliação
  • Desai N; Department of Anaesthesia, Guy's and St Thomas' NHS Foundation Trust.
  • Albrecht E; King's College London, London, United Kingdom.
Curr Opin Anaesthesiol ; 36(5): 533-540, 2023 Oct 01.
Article em En | MEDLINE | ID: mdl-37314172
PURPOSE OF REVIEW: Moderate-to-severe pain is common and remains a significant problem. Compared with opioid analgesia alone, single-shot peripheral nerve blockade has been associated with improved pain relief and the potential of decreased side effects. Single-shot nerve blockade, however, is limited by its relatively short duration of action. In this review, we aim to summarize the evidence related to local anaesthetic adjuncts for peripheral nerve blockade. RECENT FINDINGS: Dexamethasone and dexmedetomidine exhibit characteristics that most closely resemble the ideal local anaesthetic adjunct. In upper limb block, dexamethasone has been demonstrated to be superior to dexmedetomidine regardless of administration route for the duration of sensory and motor blockade as well as the duration of analgesia. No clinically significant differences between intravenous and perineural dexamethasone were found. Perineural and intravenous dexamethasone have the potential to prolong sensory blockade to a greater extent than motor blockade. The evidence indicates that the mechanism of action of perineural dexamethasone in upper limb block is systemic in nature. Unlike perineural dexmedetomidine, intravenous dexmedetomidine has not been shown to result in differences in the characteristics of regional blockade compared with local anaesthetic alone. SUMMARY: Intravenous dexamethasone is the local anaesthetic adjunct of choice, increasing the duration of sensory and motor blockade as well as the duration of analgesia by 477, 289 and 478 min, respectively. In view of this, we recommend consideration of the intravenous administration of dexamethasone at a dose of 0.1-0.2 mg/kg for all patients undergoing surgery whatever the level of postoperative pain, mild, moderate or severe. Further research should focus on the potential synergism of action between intravenous dexamethasone and perineural dexmedetomidine.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dexmedetomidina / Anestésicos Locais Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dexmedetomidina / Anestésicos Locais Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article